摘要
目的观察探讨立哌唑联合帕利哌酮治疗青年女性难治性精神分裂症的疗效及对认知功能影响,探讨青年女性难治性精神分裂症患者的治疗新策略。方法选取2016年9月~2018年9月我院确诊的难治性精神分裂症青年女性患者66例,按照随机数字表法分为对照组和观察组,各33例,对照组仅给予帕利哌酮治疗,观察者组给予帕利哌酮联合阿立哌唑治疗,对比两组患者治疗前后PANSS、MoCA评分及治疗后的临床疗效和不良反应情况。结果治疗前,两组患者PANSS评分差异无统计学意义(P> 0.05);治疗2个月后,观察组的PANSS评分显著低于对照组(P <0.05),观察组的Mo CA评分显著高于对照组(P <0.05);观察组总有效率显著高于对照组(P <0.05);两组患者不良反应发生率比较差异有统计学意义(P <0.05)。结论阿立哌唑联合帕利哌酮治疗难治性精神分裂症青年女性患者的疗效确切,可改善患者认知功能,减少不良反应发生,可作为难治性精神分裂症青年女性患者较理想的用药选择。
Objective To observe and explore the curative effects of aripiprazole combined with paliperidone in treatment of young women with refractory schizophrenia and its effect on cognitive function so as to explore new strategies for the treatment of refractory schizophrenia in young women. Methods 66 young women with refractory schizophrenia and its effect on cognitive function who were diagnosed in our hospital from September 2016 to September 2018 were selected.According to the random number table,they were divided into the control group and the observation group,with 33 cases in each group.The control group was treated with paliperone alone while the observation group was treated with paliperone combined with aripiprazole.The PANSS and MoCA scores before and after treatment and clinical curative effects and adverse reactions after treatment were compared between the two groups. Results There was no significant difference in PANSS score between the two groups before treatment (P > 0.05).After 2 months of treatment,the PANSS score of the observation group was significantly lower than that of the control group (P < 0.05),and the MoCA score of the observation group was significantly higher than that of the control group (P < 0.05).The total effective rate of the observation group was significantly higher than that of the control group (P < 0.05).There were significant differences in the incidence of adverse reactions between the two groups (P < 0.05). Conclusion Aripiprazole combined with paliperidone in treatment of young women with refractory schizophrenia has accurate curative effects.It can improve the cognitive function of patients and reduce the occurrence of adverse reactions,which can be used as an ideal drug choice for young women with refractory schizophrenia.
作者
吴广兵
余为陆
宋尚琪
刘嘉斌
WU Guangbing;YU Weilu;SONG Shangqi;LIU Jiabin(Sixth Department of Psychiatry,the Third People's Hospital of Meizhou,Meizhou 514089,China)
出处
《中国医药科学》
2019年第9期58-61,共4页
China Medicine And Pharmacy